Clinical Trials Logo

Esophagitis, Peptic clinical trials

View clinical trials related to Esophagitis, Peptic.

Filter by:

NCT ID: NCT01778101 Completed - Preterm Infants Clinical Trials

Lansoprazole in Preterm Infants With Reflux

Start date: January 2013
Phase: Phase 2
Study type: Interventional

This study is pilot study to evaluate safety and efficacy of lansoprazole in preterm infants with gastroesophageal reflux documented by 24hr pH impedance monitoring

NCT ID: NCT01733810 Completed - Clinical trials for Gastroesophageal Reflux Disease

The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis

Start date: February 1, 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the role of hypoxia inducible factor (HIF)-2a on the production of inflammatory cytokines that lead to reflux esophagitis.

NCT ID: NCT01669811 Completed - Clinical trials for Refractory Reflux Esophagitis

Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)

Start date: August 2012
Phase: Phase 3
Study type: Interventional

This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of esomeprazole magnesium salt) with refractory reflux esophagitis after 8 weeks of standard Proton-pump inhibitor (PPI) therapy by assessment of presence/absence of inflammation (esophagitis) at Week 8 according to the Los Angeles (LA) classification

NCT ID: NCT01599858 Completed - Reflux Oesophagitis Clinical Trials

Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers

Start date: August 1996
Phase: Phase 1
Study type: Interventional

The objectives of this study were: To compare repeated doses of YF476 at 2 dose levels, placebo and omeprazole with respect to their effect on basal- and food- stimulated gastric pH in healthy volunteers. To compare repeated doses of YF476 at 2 dose levels, placebo and omeprazole with respect to their effect on basal and meal stimulated pH. To assess the safety, tolerability and pharmacokinetics of repeated doses of YF476 in healthy volunteers.

NCT ID: NCT01597674 Completed - Reflux Oesophagitis Clinical Trials

Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers

Start date: April 1997
Phase: Phase 1
Study type: Interventional

The objective of the study was to assess whether the tolerance to the effect of YF476 on gastric pH observed with repeated doses in a previous study in healthy volunteers can be avoided by using smaller doses of YF476.

NCT ID: NCT01562639 Completed - Clinical trials for Repeatedly Recurring Esophagitis

Nexium Capsules RE Maintenance Specific Clinical Experience Investigation

Start date: April 2012
Phase: N/A
Study type: Observational

The purpose of this study is to collect following data in patients given Nexium capsule (Nexium) in usual post-marketing use as the maintenance therapy for repeatedly recurring/relapsing reflux oesophagitis.

NCT ID: NCT01538849 Completed - Reflux Esophagitis Clinical Trials

Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis

Start date: December 2012
Phase: Phase 2
Study type: Interventional

This study is to investigate the optimal clinical dose and administration methods of YH4808 in patients with reflux esophagitis by evaluating the safety and efficacy after YH4808 oral administration.

NCT ID: NCT01538797 Completed - Reflux Oesophagitis Clinical Trials

Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States

Start date: July 1996
Phase: Phase 1
Study type: Interventional

The objectives of the study were: - To compare a single dose of YF476 at 3 dose levels, placebo and ranitidine with respect to their effects on basal- and food- stimulated gastric pH in healthy volunteers. - To assess whether there is a relationship between the pharmacokinetics of YF476 and gastric pH in healthy volunteers. - To assess the safety and tolerability of single doses of YF476 in healthy volunteers.

NCT ID: NCT01538784 Completed - Reflux Oesophagitis Clinical Trials

Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men

Start date: May 1996
Phase: Phase 1
Study type: Interventional

The objectives of the study were: - To assess the safety, tolerability and pharmacokinetics of YF476 in healthy volunteers. - To select a dose or doses of YF476 for detailed pharmacodynamic studies in healthy volunteers.

NCT ID: NCT01536080 Completed - Clinical trials for Non-erosive Reflux Disease (NERD)

Analysis of GERD Symptoms Using Gastroesophageal Reflux Impact Score Questionnaire for Quality of Life

Start date: July 2008
Phase: N/A
Study type: Observational

Even the patients complain GERD symptoms such as heartburn and acid regurgitation the final diagnosis could be reflux esophagitis (RE), non-erosive reflux disease (NERD) and even functional heartburn (FH). In addition, the GERD symptoms are consisted of esophageal symptoms and extraesophageal symptoms. Thus it is necessary to use effective tool for the measurement of GERD symptoms and response of proton pump inhibitor in short time. Several questionnaires have been made for the assessment of GERD symptoms in recent years However, their screening tools do not include the impact of symptoms on everyday life and take a long time to complete the questionnaires. The GERD impact scale (GIS) questionnaire has been developed to compensate for this. It is a simple, one-page, questionnaire to communicate to the doctor the frequency of reflux symptoms and their effect on quality of life, recognizing that it might also prompt clinicians to make appropriate treatment for patients' symptoms. However, there was no report regarding comparison of the characteristics and response to PPI in RE, NERD and FH groups using GIS questionnaire so far.